この論文をさがす
説明
<jats:title>ABSTRACT</jats:title><jats:p>Glutamate regulates the function of central nervous system (CNS), in part, through the cAMP and/or IP3/DAG second messenger‐associated metabotropic glutamate receptors (mGluRs). The mGluR5 antagonist 2‐methyl‐6‐(phenylethynyl)‐pyridine (MPEP) has been extensively used to elucidate potential physiological and pathophysiological functions of mGluR5. Unfortunately, recent evidence indicates significant non‐specific actions of MPEP, including inhibition of NMDA receptors. In contrast, in vivo and in vitro characterization of the newer mGluR5 antagonist 3‐[(2‐methyl‐1,3‐thiazol‐4‐yl)ethynyl]pyridine (MTEP) indicates that it is more highly selective for mGluR5 over mGluR1, has no effect on other mGluR subtypes, and has fewer off‐target effects than MPEP. This article reviews literature on both of these mGluR5 antagonists, which suggests their possible utility in neurodegeneration, addiction, anxiety and pain management.</jats:p>
収録刊行物
-
- CNS Drug Reviews
-
CNS Drug Reviews 12 (2), 149-166, 2006-06
Wiley